Hyperbaric Oxygen Therapy for Moderate to Severe Ulcerative Colitis Flares: A Multi-center Randomized Double Blind Sham Controlled Trial
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Ulcerative Colitis
- Sponsor
- Dartmouth-Hitchcock Medical Center
- Enrollment
- 18
- Locations
- 3
- Primary Endpoint
- Primary Response
- Status
- Terminated
- Last Updated
- 8 years ago
Overview
Brief Summary
The investigators aim to prospectively study the feasibility and clinical impact of hyperbaric oxygen therapy in acute hospitalized moderate to severe ulcerative colitis flares as an adjunct to standard medical treatment. Specifically, we will investigate the impact of hyperbaric oxygen therapy on clinical response/remission and serum and mucosal inflammatory markers. The investigators expect that hyperbaric oxygen therapy will improve patient responsiveness to steroids and avoid progression to second line therapy during hospitalization.
Investigators
Corey Siegel
Section Chief, Section of Gastroenterology
Dartmouth-Hitchcock Medical Center
Eligibility Criteria
Inclusion Criteria
- •known or newly diagnosed moderate to severe ulcerative colitis with a Mayo score of greater than 6
- •Mayo endoscopic sub-score of greater than or equal to 2
- •Risk score of greater than or equal to 4 points
Exclusion Criteria
- •Complication requiring urgent surgical intervention (in the opinion of the investigators)
- •Clinically significant cardiac, renal, neurological, endocrine, respiratory or hepatic impairment in the opinion of the investigator, including but not limited to:
- •Pulmonary i. COPD with CO2 retention; Previous/current imaging showing hyperinflation/air trapping/bullous disease/blebs (opinion of investigators) ii. Current pneumothorax or previous spontaneous pneumothorax iii. Bronchogenic cyst(s)
- •Cardiac i. Uncontrolled HTN (systolic \>160 or diastolic \>100) ii. Unstable angina or myocardial infarction within the previous 3 months iii. Ejection fraction \< 35% iv. Current or previous amiodarone use v. ICD in place vi. Pacemaker in place not approved for chamber use
- •Hematological/Oncological i. Current chemotherapeutic drug use, and past history of bleomycin use. ii. Hereditary Spherocytosis iii. Sickle cell anemia
- •Gastrointestinal and Infectious Disease i. Known or suspected Crohn's disease ii. Previous infection with mycobacterium, fungus, HIV, Hepatitis B or C iii. Gastrointestinal or systemic infection including, but not limited to, --Clostridium difficile iv. Current capsule endoscopy or previously non-retrieved capsule Endocrinology i. Uncontrolled hyperthyroidism
- •Neurological and Psychological i. Vagal or other nerve stimulators
- •ii. Uncontrolled seizure disorder
- •iii. Medications or medical conditions that lower seizure threshold (in the opinion of the investigator) iv. Drug or alcohol abuse/dependence v. Current treatment for alcohol cessation with disulfiram vi. Current or recent (within past week) use of baclofen Head and Neck i. Previous middle ear damage, surgery or infection(s) which may increase the risk for needing ear tubes (in the opinion of the investigator) ii. Current or previous retinal detachment or optic neuritis iii. Retinal or vitreous surgery within the past 3 months Miscellaneous i. Implanted devices not on the approved list for use with HBOT
- •Women who are pregnant or nursing. Women with childbearing potential were required to use effective birth control if not surgically sterile or postmenopausal for \>2 years.
Outcomes
Primary Outcomes
Primary Response
Time Frame: Day 5
Impact of hyperbaric oxygen therapy on clinical response/remission to medical therapy as measured by the partial Mayo score at study day 5. Clinical remission will be defined as a partial Mayo score of less than or equal to 2 with no individual sub-score exceeding 1 point. Clinical response will be defined as a decrease in partial Mayo score greater than or equal to 2 points with a decrease in rectal bleeding sub-score of greater than or equal to 1 point, or an absolute rectal bleeding sub-score of 0 or 1.
Secondary Outcomes
- Reduction in Full Mayo Score(Day 10)
- Reduction in Inflammatory Markers(Day 10)
- Progression to Second Line Therapy(Day 10)